Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 3 3Phase 2 3Phase 1/2 2

Status

Completed 3

Sponsor Class

OTHER 3INDUSTRY 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1Genitourinary 1

Conditions

Carcinoma, Hepatocellular 2Sarcoma 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × brivanib × Clear all
NCT00355238 2023-12-01

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

Bristol-Myers Squibb

Phase 2 Completed
137 enrolled 20 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT03516071 2019-09-04

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Zai Lab (Hong Kong), Ltd.

Phase 2 Completed
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00633789 2015-10-09

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Bristol-Myers Squibb

Phase 2 Completed
597 enrolled
GastrointestinalGenitourinarySarcoma

Adenocarcinoma Of Esophagus, Carcinoma, Transitional Cell, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡